Study Name Principal Investigator
(FEDR-MF-001) A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib (The “FREEDOM” trial) Kota, Vamsi
(IDR-OM-02) A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck Guddati, Achuta
(KEYLYNK-010) A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy Parikh, Jigarkumar
(KEYNOTE-641) A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Parikh, Jigarkumar
(KEYNOTE-921) A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) Parikh, Jigarkumar
(Lung Nodule) A Study to Evaluate a Panel of Blood Biomarkers for Use in Patients Undergoing Evaluation for Lung Cancer, Onc-Ln-04 Islam, Shaheen
1948-CL-0101: A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors Ghamande, Sharad
4010-03-001 / ENGOT EN-6 / GOG-3031: A phase 3, randomized, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer (RUBY) Ghamande, Sharad
A Multicentre Randomised Phase II Study of AZD1775 plus Chemotherapy versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Ghamande, Sharad
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer Ghamande, Sharad
A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR-214 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS Abdel Karim, Nagla
A PHASE 1/2A, MULTICENTER, OPEN-LABEL STUDY OF LYC-55716 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CANCER Ghamande, Sharad
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001) Ghamande, Sharad
A phase Ib /II trial of pembrolizumab and idelalisib in patients with non-small cell lung cancer (NSCLC) who have failed immune checkpoint inhibitor Hao, Zhonglin
A PHASE II TRIAL EVALUATING CISPLATIN (NSC #119875) AND GEMCITABINE (NSC # 613327) CONCURRENT WITH INTENSITY-MODULATED RADIATION THERAPY (IMRT) IN THE TREATMENT OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE VULVA Ghamande, Sharad
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA) Ghamande, Sharad
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients with Advanced Gynecological Cancers (CL-PTL-126) Ghamande, Sharad
A011106; ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study Ghamande, Sharad
A011401; Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Ghamande, Sharad
A011502: A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial Ghamande, Sharad
A191402CD; TESTING DECISION AIDS TO IMPROVE PROSTATE CANCER DECISIONS FOR MINORITY MEN Ghamande, Sharad
ADXS001-04: Phase 1-2 Study of MEDI4736 Alone or In Combination with ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer Ghamande, Sharad
Agenus C-550-01: A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors Ghamande, Sharad
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009) (MK7339-009) Krutchik, Allan
AVA-CIT-330: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancer Ghamande, Sharad
B1371019: A RANDOMIZED (1:1), DOUBLE BLIND, MULTI CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF 04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA Cortes, Jorge
B1761031: A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA Kota, Vamsi
BAT Cancer at the VA Toscano, Michael
Biomarkers and Therapies for Cancer (BAT Cancer) She, Jin-Xiong
BST002: A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly Diagnosed Acute Myeloid Leukemia, Not Eligible for Standard Induction Therapy Pantin, Jeremy
C-145-04: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma Ghamande, Sharad
CO-338-043: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Ghamande, Sharad
D081RC00001 A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) Ghamande, Sharad
D419BR00008: PREVAIL A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma Parikh, Jigarkumar
EA1131 A Randomized Phase III Post Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy Ghamande, Sharad
EA4151; A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission Ghamande, Sharad
Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients with Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to Therapy: The EMPATHY Pilot Study Kota, Vamsi
FPA150-001: A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients with Advanced Solid Tumors Ghamande, Sharad
GCC20-009: Phase I feasibility and safety study of nivolumab in combination with irinotecan followed by maintenance nivolumab in relapsed or refractory small cell lung cancer (SCLC) patients who progressed on chemotherapy or chemo-immunotherapy Karim, Nagla
GCT1015-05/GOG 3024: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer Ghamande, Sharad
GOG 0264: A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VS. BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED ADVANCED STAGE AND RECURRENT CHEMONAIVE STAGE SEX CORD-STROMAL TUMORS OF THE OVARY Ghamande, Sharad
GOG 3028/C-750-01: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS Ghamande, Sharad
GSK 205744: A Phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult subjects with IPSS-R high and very high risk myelodysplastic syndromes (MDS) previous treated with hypomethylating agents (HMA) Pantin, Jeremy
INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft Versus Host Disease (GRAVITAS-309) Kota, Vamsi
Incuron I137-102: A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers Bryan, Locke
IST65: Phase I study of cabozantinib in combination with pemetrexed in advanced non-squamous non-small cell lung cancer (NSCLC), urothelial cancer and advanced malignant mesothelioma Abdel Karim, Nagla
MK-7902-010: A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as first-line intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010) Guddati, Achuta
MK3475-826 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826) Ghamande, Sharad
MORAb-003-011: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Ghamande, Sharad
MS100070_0176: An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies Parikh, Jigarkumar
MS201943-0029: A Phase Ib, Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Ghamande, Sharad
NewLink Genetics NLG-2106: A Phase 1 / Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Pantin, Jeremy
NMTRC 014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO) McDonough, Colleen
NMTRC012: PEDS-PLAN--Pediatric Precision Laboratory Advanced Neuroblastoma Therapy - A study using molecular guided therapy with induction chemotherapy followed by a randomized controlled trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for subjects with newly diagnosed high-risk neuroblastoma McDonough, Colleen
NRG-GY007, A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Ghamande, Sharad
NRG-GY009; A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Ghamande, Sharad
NU 16H07: Phase II Trial of Pembrolizumab in Combination with ICE Salvage Chemotherapy for Relapsed /Refractory Hodgkin Lymphoma Bryan, Locke
ONC-DPX-Survivac-06: A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer Ghamande, Sharad
ONT-380-206: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma Parikh, Jigarkumar
Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG Johnson, Theodore
PrE0905: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) Kota, Vamsi
Retrospective Review of Head and Neck Cancer Patients Byrd, J. Kenneth
REVEAL 2: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) OF THE CERVIX Ferris, Daron
S1415CD; A PRAGMATIC TRIAL TO EVALUATE A GUIDELINE-BASED COLONY STIMULATING FACTOR STANDING ORDER INTERVENTION AND TO DETERMINE THE EFFECTIVENESS OF COLONY STIMULATING FACTOR USE AS PROPHYLAXIS FOR PATIENTS RECEIVING CHEMOTHERAPY WITH INTERMEDIATE RISK FOR FEBRILE NEUTROPENIA –TRIAL ASSESSING CSF PRESCRIBING EFFECTIVENESS AND RISK (TRACER) Ghamande, Sharad
S1605; Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Ghamande, Sharad
SGN22E-001: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy Parikh, Jigarkumar
SGNTV-002 - Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen Ghamande, Sharad
TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ghamande, Sharad
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection Ferris, Daron
Translational Research in Benign and Malignant Genitourinary, Gastrointestinal, and Breast Diseases. Lokeshwar, Vinata
TRX518-004: A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Nayak-Kapoor, Asha
Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial Byrd, Kenneth
Utility of Pre-Operative Stellate Ganglion Blockade for Pain Control in Unilateral Head and Neck Cancer Surgery Byrd, Kenneth
Vedolizumab-3035: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Kota, Vamsi
RESEARCH. INNOVATION. DISCOVERY.